This article has been updated from a previous version to clarify the nature of the partnership between Evosep and Thermo Fisher.
NEW YORK (GenomeWeb) – Thermo Fisher Scientific and Evosep announced on Monday a partnership to develop and promote workflows for clinical proteomics.
The collaboration will be centered out of Thermo Fisher's Boston-based Precision Medicine Science Center and will combine its mass spec systems with Evosep's liquid chromatography to develop robust, high-throughput clinical proteomic methods, the companies said.
Financial and other terms of the agreement were not disclosed.
"We are using the Evosep One in our new Precision Medicine Science Center… where we have established workflows for the rapid analysis of plasma and FFPE samples," Ken Miller, vice president of omics marketing at Thermo Fisher, said in a statement. "The system works seamlessly with our Q Exactive MS systems and the Evotip technology improves overall system throughput and robustness by reducing column clogging and carryover."
"The Evosep One with its novel sample separation solution offers market-leading throughput to cope with the significantly larger cohort sizes of typical clinical studies," Nicolai Bache, Evosep's head of applications," said. "Researchers are now seeking to include plasma proteomics in an increasing number of clinical studies and therefore it becomes important for the community to have instruments and consumables that are tailored for the task."